Catalog No.
Product Name
Application
Product Information
Citations
-
ADC Cytotoxin
N-Ac-γ-Calicheamicin-AcBut-NHS ester is an ADC cytotoxin that induces cell cycle arrest and apoptosis through the formation of DNA double-strand breaks. This compound is primarily utilized in the synthesis of antibody-drug conjugates (ADCs) and is particularly relevant in cancer research, including studies related to acute lymphoblastic leukemia (ALL) and various hematological malignancies. Its potent cytotoxic properties make it a valuable tool for advancing therapeutic strategies in oncology. -
ADC Cytotoxin
Hydrotecan is a derivative of Camptothecin, specifically designed as an antibody-drug conjugate (ADC) cytotoxin. It exhibits potent antitumor activity by inducing apoptosis in cancer cells through its action on topoisomerase I. This compound is valuable for the synthesis of ADC molecules, facilitating targeted cancer therapy research and development. -
ADC Cytotoxin
DC0-NH2 is an effector moiety targeting antibody-drug conjugates (ADCs) with enhanced stability compared to its analog DC1. This compound exhibits remarkable cytotoxicity, demonstrating approximately 1000-fold greater potency than traditional anticancer agents like Doxorubicin. The mechanism involves binding to the minor groove of DNA, leading to alkylation of adenine residues via its propabenzindole (CBI) moiety, making it a valuable candidate for cancer research and therapeutic applications. -
ADC Cytotoxin
DM3, a Maytansine analog, is a potent tubulin inhibitor that contains disulfide or thiol groups. As a key cytotoxic component of antibody-drug conjugates (ADCs), DM3 is designed to selectively target and eliminate cancer cells. Its ability to disrupt microtubule formation makes it valuable in cancer research and the development of targeted therapies. -
ADC Cytotoxin
7-MAD-MDCPT hydrochloride is a Camptothecin analog that serves as a cytotoxic payload in antibody-drug conjugates (ADCs). This compound demonstrates potent anti-cancer activity by targeting topoisomerase I, leading to DNA damage and subsequent apoptosis in cancer cells. It is primarily utilized in research focused on developing targeted cancer therapies and enhancing the efficacy of ADCs. -
ADC Cytotoxin
7-Aminomethyl-10-methyl-11-fluoro camptothecin is a potent cytotoxin targeting cancer cells through its mechanism of acting as a topoisomerase inhibitor. This compound serves as an essential intermediate for the synthesis of camptothecin-based antibody-drug conjugates (ADCs), which are designed to deliver targeted therapeutic agents to tumor cells. Its applications in cancer research support the development of innovative treatments aimed at improving the efficacy of chemotherapy while reducing systemic toxicity. -
ADC Cytotoxin
Tomaymycin DM is a derivative of tomaymycin that acts as a DNA alkylating agent, functioning primarily as a payload in antibody-drug conjugates (ADCs). This compound exhibits potent cytotoxic activity, targeting tumor cells through selective delivery mechanisms associated with ADCs. Tomaymycin DM is essential for research into targeted cancer therapies and the development of novel ADC formulations. -
ADC Cytotoxin
Exatecan Intermediate 2 hydrochloride is a cytotoxic agent targeting DNA through its mechanism as a camptothecin analog. This compound plays a critical role in the synthesis of Exatecan, an anticancer agent known for its efficacy against various malignancies, including ovarian, lung, and breast cancers. Exatecan Intermediate 2 hydrochloride is primarily utilized in research focused on cancer biology and therapeutic development. -
ADC Cytotoxin
Exatecan Intermediate 4, a key intermediate in the synthesis of Exatecan (DX-8951), functions as an ADC cytotoxin. This compound exhibits potent antitumor activity by disrupting DNA replication, leading to the inhibition of cancer cell proliferation. It is utilized in research related to various malignancies, including ovarian, lung, and breast cancers, providing insights into targeted cancer therapies and drug development. -
ADC Cytotoxin
PNU-159682 carboxylic acid is a potent cytotoxin utilized in antibody-drug conjugates (ADCs) targeting the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily. This compound exhibits diverse biological activities, including modulation of cell adhesion, cell-cell signaling, and glycoprotein turnover. It plays significant roles in inflammation and immune response, making it valuable for research applications in oncology and immunology. -
ADC Cytotoxin
Maytansinoid DM4 is a thiol-containing maytansine derivative that serves as a potent cytotoxic agent. Acting as a key component in antibody-drug conjugates (ADCs), it exhibits significant biological activity by selectively targeting and destroying cancer cells. This compound is instrumental in advancing therapeutic strategies for cancer treatment research. -
ADC Payload
(1R,9S)-Dxd is an isomer of Dxd and serves as an antibody-drug conjugate (ADC) payload. Its primary mechanism involves targeted delivery of cytotoxic agents, enhancing the specificity and efficacy of ADCs in cancer therapy. This compound is utilized in the synthesis of various ADC formulations for research applications focused on improving therapeutic outcomes in oncology. -
ADC Cytotoxin
INX-SM-56 is a cytotoxin specifically designed for the synthesis of anti-VISTA antibody-drug conjugates. Targeting VISTA (V-region Immunoglobulin-containing Suppressor of T cell Activation), this compound enhances the cytotoxic efficacy of therapeutic antibodies. It is primarily utilized in cancer research to investigate immune modulation and therapeutic strategies against tumor progression. -
ADC Linker
DeBoc-Cabazitaxel serves as a versatile ADC linker, facilitating the conjugation of antibodies to cytotoxic agents for targeted therapy. This compound enhances the efficacy of antibody-drug conjugates (ADCs) by enabling selective delivery to tumor cells while minimizing off-target effects. It is particularly valuable in the development of novel cancer therapies, supporting research in targeted anti-tumor strategies. -
ADC linker
Dap-NE is an intermediate reagent specifically designed for use in the synthesis of antibody-drug conjugates (ADCs), particularly the cytotoxic agent Monomethyl auristatin E. Its role as a linker plays a critical part in ensuring the efficient delivery of therapeutic agents to targeted cells, enhancing the efficacy of the ADC. This compound is essential for researchers investigating novel ADC formulations and their applications in cancer therapeutics. -
ADC Cytotoxin
DMEA-PNU-159682 is an antibody-drug conjugate (ADC) cytotoxin that combines the metabolites of nemorubicin (MMDX) with the potent cytotoxic agent PNU-159682. This compound exhibits significant cytotoxicity, making it a valuable tool for targeted cancer therapies. Its unique mechanism of action allows for selective delivery of cytotoxic agents to tumor cells, thereby enhancing therapeutic efficacy while minimizing off-target effects in research applications focused on ADC development and optimization. -
ADC Cytotoxin
DC4 is an ADC cytotoxin utilized in the synthesis of antibody-drug conjugates (ADCs). This compound facilitates targeted cancer therapy, enabling the selective delivery of cytotoxic agents to malignant cells while minimizing effects on healthy tissue. Its applications are particularly relevant in oncology research focused on enhancing the efficacy of cancer treatments through targeted delivery mechanisms. -
ADC Cytotoxin
DC4SMe is a phosphate proagent of the cytotoxic DNA alkylator DC4, designed for use in the synthesis of antibody-drug conjugates (ADCs). Exhibiting low IC50 values of 1.9 nM, 2.9 nM, and 1.8 nM against Ramos, Namalwa, and HL60/s cancer cell lines, respectively, DC4SMe demonstrates potent anti-cancer activity. This compound is suitable for research applications focused on targeted cancer therapies. -
ADC Cytotoxin
Diacetyl Agrochelin is an acetyl derivative of Agrochelin, targeting ADC cytotoxins for therapeutic applications. This compound demonstrates significant cytotoxic activity in various tumor cell lines, making it valuable for cancer research and development of targeted anticancer therapies. Its unique mechanism of action supports investigations into the efficacy of antibody-drug conjugates in oncological studies. -
ADC Payload
TNF-α Agonistic 2 is an agonist targeting tumor necrosis factor-alpha (TNF-α), functioning primarily as an antibody-drug conjugate (ADC) payload. This compound exhibits significant biological activity by reducing tissue thickness, as evidenced by its effects on murine models. It is applicable in research related to targeted cancer therapies and may facilitate the study of TNF-α's role in immune modulation and tumor microenvironment interactions. -
ADC Payload
Auristatin S is a potent antitumor agent designed as a payload for antibody-drug conjugates (ADCs). It exhibits significant cytotoxic activity while mitigating bystander effects and enhancing off-target toxicity profiles. Auristatin S demonstrates excellent tolerability in Karpas and KarpasBVR cell models, making it a valuable tool for targeted cancer therapies across various tumor types. Its unique properties support its application in the development of effective ADCs for cancer treatment research. -
ADC Cytotoxin
DMEA-PNU-159682 dichloroacetate acts as an antibody-drug conjugate (ADC) cytotoxin, incorporating metabolites of nemorubicin (MMDX) generated from liver microsomes along with the potent cytotoxic agent PNU-159682. This compound exhibits significant biological activity by selectively targeting cancer cells, enabling targeted delivery and enhanced therapeutic efficacy. DMEA-PNU-159682 is applicable in cancer research, specifically in studies focusing on ADC development and the evaluation of cytotoxic mechanisms. -
ADC Cytotoxin
Gly-Cyclopropane-Exatecan functions as a key component in the synthesis of antibody-drug conjugates (ADCs) targeting B7-H4. It incorporates Exatecan, a potent DNA Topoisomerase I inhibitor, into the ADC hu2F7-Exatecan, which has demonstrated significant antitumor efficacy in vivo and in vitro. This compound is relevant for cancer research, particularly in the development of targeted therapy strategies against tumor cells expressing B7-H4. -
ADC Cytotoxin
Muscotoxin A is an ADC cytotoxin that functions as a cytotoxic lipopeptide. It effectively permeabilizes mammalian cell membranes, leading to the induction of necrotic cell death. This compound is valuable in research applications involving targeted cancer therapies and the study of cellular responses to membrane disruption. -
ADC Cytotoxin
Dimethyl-SGD-1882 is a highly potent DNA alkylator, specifically designed for use as an antibody-drug conjugate (ADC) cytotoxin. It acts by forming covalent bonds with DNA, leading to the inhibition of DNA replication and subsequent induction of cytotoxicity in rapidly dividing cancer cells. This compound is valuable for research applications focused on targeted cancer therapies and the development of novel ADCs. -
ADC Cytotoxin
7-MAD-MDCPT TFA is a Camptothecin analog that serves as a cytotoxic payload for antibody-drug conjugates (ADCs). Its mechanism targets topoisomerase I, leading to the induction of apoptosis in malignant cells. This compound is relevant for research applications focused on cancer therapy, particularly in the development of targeted treatment strategies that enhance the efficacy of ADCs. -
ADC Payload
DUBA is a potent DNA alkylating agent that serves as an effective antibody-drug conjugate (ADC) payload. By covalently binding to DNA, DUBA disrupts replication and transcription processes, leading to cytotoxic effects in targeted cancer cells. Its application in synthesizing ADCs enables enhanced specificity and efficacy in delivering therapeutic agents directly to tumor sites, aiding in cancer research and treatment development. -
ADC Payload
Cryptophycin analog 1 is a potent antibody-drug conjugate (ADC) payload that targets and disrupts cancer cell proliferation. Exhibiting significant anticancer activity, this compound demonstrates cellular efficacy that is an order of magnitude greater than established ADC payloads such as MMAE and DM1. Its enhanced potency makes it a valuable tool for research in targeted cancer therapies. - Mc-Gly-Gly-Phe-Gly-PAB-OH (Mc-GGFG-PAB-OH) is a cleavable ADC linker used for antibody-drug conjugates (ADCs).
-
Drug-Linker Conjugate for ADC
Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications. It features a linker alongside the potent cytotoxic agent MMAE, enabling targeted delivery to cells expressing the c-Kit receptor. This compound can facilitate the synthesis of NN3201 by conjugating with NN2101 (anti c-Kit), which promotes rapid internalization and effectively disrupts SCF-driven signaling pathways. Consequently, NN3201 demonstrates significant anti-tumor activity in various cancer models, including small cell lung cancer (SCLC) and gastrointestinal stromal tumors (GIST). -
Antibody-Drug Conjugate
Loncastuximab tesirine is an antibody-drug conjugate (ADC) targeting the cluster of differentiation 19 (CD19) antigen. This compound comprises the Loncastuximab antibody linked to Tesirine, a potent cytotoxic agent. Upon binding to CD19, Loncastuximab tesirine is internalized, leading to apoptosis in malignant B-cells. This reagent is primarily utilized in research focused on diffuse large B-cell lymphoma and related hematological malignancies. -
Antibody-Drug Conjugate
Depatuxizumab mafodotin is an antibody-drug conjugate (ADC) that specifically targets the epidermal growth factor receptor (EGFR). This reagent exhibits potent antitumor activity and is valuable for research applications involving glioma, head and neck squamous cell carcinoma, non-small cell lung cancer, epidermoid carcinoma of the skin, and squamous cell carcinoma of the tongue. Its mechanism of action combines selective targeting of EGFR with cytotoxic delivery, making it a significant tool in cancer research and therapeutic studies. -
Antibody-Drug Conjugates
Calotatug ginistinag (XMT-2056) is an antibody-drug conjugate that targets HER2, featuring a potent payload linked to a STING agonist. This innovative design promotes immune activation, enhancing anticancer efficacy. Its applications are particularly relevant in the development of targeted therapies for HER2-positive cancers, making it a valuable tool for cancer research. -
Antibody-drug Conjugate
Trastuzumab emtansine is an antibody-drug conjugate (ADC) that combines the HER2-targeting capabilities of trastuzumab with the cytotoxic effects of the microtubule-inhibitory agent DM1. This compound demonstrates potent antitumor activity and is particularly relevant in the study of advanced breast cancer. Its dual mechanism allows for targeted delivery of cytotoxic agents, making it a valuable tool in oncological research and therapeutic development. -
Antibody-Drug Conjugate
Disitamab vedotin is an antibody-drug conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2). This reagent consists of a monoclonal antibody linked through a cleavable connector to the cytotoxic drug Monomethyl auristatin E (MMAE). Disitamab vedotin is designed to enhance antitumor immunity and is applicable in cancer research, particularly in studies focused on HER2-positive malignancies. -
ADC Linker
DBCO-NHS ester is a non-cleavable linker utilized in the synthesis of antibody-drug conjugates (ADCs). It serves as a click chemistry reagent, featuring a DBCO moiety that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. This compound is essential for bioconjugation applications, allowing for the stable attachment of therapeutics to antibodies, thereby enhancing the efficacy and specificity of targeted drug delivery in cancer research. -
ADC Linker
Sulfo-SMCC sodium is a hetero-bifunctional ADC linker that features both an N-hydroxysuccinimide (NHS) ester and a maleimide functional group. It facilitates efficient coupling by selectively reacting with primary amines and sulfhydryl groups, forming stable noncleavable linkages. This reagent is widely employed in the development of antibody-drug conjugates (ADCs), enabling targeted delivery of therapeutic agents for enhanced efficacy in cancer treatment and other diseases. -
ADC Linker
Desthiobiotin-Iodoacetamide functions primarily as an antibody-drug conjugate (ADC) linker, facilitating targeted drug delivery in therapeutic applications. It exhibits a strong affinity for biotin-binding proteins, making it useful in the labeling and detection of proteins in various biological assays. Additionally, this compound can be utilized as a probe for studying Oridonin-treated cell lysis, enhancing the understanding of cellular responses in drug treatment studies. -
Labling Agent
DOTA-NHS-ester is a labeling agent that facilitates the conjugation of affibody molecules for applications in molecular imaging. It is commonly utilized in small animal positron emission tomography (PET), single-photon emission computed tomography (SPECT), and computed tomography (CT). This reagent effectively labels radiotherapeutic agents or imaging probes, aiding in the detection and characterization of tumors. -
Azide Compound
15-Azido-pentadecanoic acid is an azide-containing compound widely utilized in click chemistry applications. This reagent is particularly effective for labeling and characterizing post-translationally palmitylated proteins through a straightforward two-step labeling process. Additionally, it can engage in copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-functionalized molecules, as well as strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with DBCO or BCN groups, providing versatile approaches for conjugation in chemical biology research. -
ADC Linker
N-Hydroxysulfosuccinimide sodium serves as a non-cleavable linker for antibody-drug conjugates (ADCs). By enabling stable covalent attachment of cytotoxic drugs to antibodies, it plays a crucial role in enhancing targeted cancer therapy. This reagent is widely utilized in the development and optimization of ADC formulations for improved therapeutic efficacy. -
PROTAC Linker
Azido-PEG2-C2-amine is a PEG-based linker designed for use in PROTAC synthesis. This compound features an azide moiety that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) and strain-promoted azide-alkyne cycloaddition (SPAAC) reactions, facilitating conjugation with alkyne-bearing molecules. Additionally, Azido-PEG2-C2-amine serves as a non-cleavable linker for the development of antibody-drug conjugates (ADCs), making it a versatile tool in chemical biology and drug discovery applications. -
ADC Linker
N3-PEG4-C2-NHS ester is a non-cleavable 4-unit polyethylene glycol (PEG) linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This compound features an azide group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions with alkyne-containing molecules. Additionally, it can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing DBCO or BCN functionalities. Due to its unique properties, N3-PEG4-C2-NHS ester is a valuable tool for the development of targeted therapeutics. -
ADC Linker
Maleimide-DOTA is a non-cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). It facilitates stable attachment of therapeutic agents to antibodies, ensuring effective delivery to target cells while maintaining the drug's biological activity. This compound plays a crucial role in ADC development for targeted cancer therapies and related research applications. -
ADC Linker
MC-Gly-Gly-Phe-Gly-NH-CH2-O-CH2COOH is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This linker facilitates the selective release of cytotoxic agents in targeted cancer therapies, enhancing therapeutic efficacy while minimizing off-target effects. Its structured design supports optimal stability and effective drug delivery, making it a valuable component in ADC research and development. -
Click Chemistry Reagent
3-Azidopropylamine is a click chemistry reagent designed for efficient bioconjugation through its azide functional group. It facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc) and ring strain-promoted alkyne-azide cycloaddition (SPAAC) with alkyne-containing molecules, including those with DBCO or BCN groups. This reagent is particularly useful in applications involving complexation and transfection of plasmid DNA, making it valuable for molecular biology and materials science research. -
ADC Linker
Fmoc-NH-PEG4-CH2CH2COOH is a cleavable linker designed for antibody-drug conjugates (ADCs), facilitating the targeted delivery of cytotoxic agents to cancer cells. This compound serves as a PEG-based PROTAC linker, enabling the construction of proteolysis-targeting chimeras (PROTACs) for efficient degradation of specific proteins in various biological contexts. It is suitable for applications in drug development and biochemical research, particularly in the fields of oncology and targeted therapeutics. -
ADC Linker
6-Azido-hexylamine is a versatile cleavable linker utilized in the development of antibody-drug conjugates (ADCs). It features an azide functional group that participates in copper-catalyzed azide-alkyne cycloaddition reactions (CuAAc) with alkyne-containing molecules. Additionally, it can engage in strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with DBCO or BCN functionalized compounds. This compound is essential for the precise attachment of cytotoxic agents to antibodies, facilitating targeted cancer therapies. -
ADC Linker
DBCO-PEG4-Maleimide is a non-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound features a DBCO group that facilitates strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, enabling efficient conjugation. It is essential for applications in targeted drug delivery, enhancing the therapeutic efficacy of ADCs while minimizing off-target effects. -
ADC Linker
Mal-PEG4-NHS ester is a non-cleavable ADC linker that facilitates the conjugation of biomolecules, particularly linking Quantum dots (QDs) with PEGylated liposomes. This compound exhibits key biological activity by enhancing the stability and solubility of the assembled conjugates. It is primarily utilized in antibody-drug conjugate (ADC) development, nanomedicine, and for improving drug delivery systems in research applications.
